Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigrima vs Perjeta in HER2+ Metastatic Breast Cancer
NCT05283837Phase 3Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in breast cancer, sponsored by Zydus Lifesciences Limited. Started Sep 2022; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05283837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283837.